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Abstract 
 
Background: Lymph node (LN) counts from pancreatectomy are postulated as quality metric for 
surgical therapy of pancreatic malignancy. 
Methods: Prospectively collected data from a single surgeon’s pancreatectomy experience were 
analyzed for predictors of LN counts. 
Results: Of 315 consecutive patients (54% female, median age: 65, range 18-88), 239 had a 
proven cancer diagnosis (76%). Operations included pancreatoduodenectomy (69%), distal 
pancreatectomy (26%), total pancreatectomy (1%) and others (4%). Patients were treated in 4 
different tertiary cancer center settings (Institution A: 11%; B: 46%; C: 27%; D: 16%) with 
consistent regional dissection standards. Mean total LN counts differed between institutions for 
malignancies (A: 18, B: 13, C: 26, D: 26, p<0.0001) and benign diseases (p=0.003). At least 15 
LNs were reported in 63% of cancer patients (institution range: 34-92%, p<0.0001). 
Conclusions: Pathologic processing should be standardized if LN numbers are to be adopted as 
quality metric for pancreatic cancer resections. 
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Background 
 
Pancreatic cancer and other periampullary cancers remain formidable health care challenges for 
which few effective therapeutic options exist. For apparently localized tumors, resection 
continues to provide some important benefit, albeit rarely curative 1. Complexity of 
pancreatectomy and a high morbidity potential call for appropriate specialty expertise when 
performing such operations. Adhering to high technical and oncological resection standards, 
among other important selection and care parameters, has become a critical mandate to deliver 
appropriate care and achieve best possible outcomes such as obtaining low rates of margin 
positivity, minimizing locoregional recurrence and prolonging survival. Although efforts to 
extend the regional dissection during pancreatectomy for cancer have failed to show measurable 
survival benefits in several randomized controlled trials 2-5, total lymph node (LN) counts after 
pancreatic resections nevertheless are linked to staging accuracy and may impact regional disease 
control 6. Conclusive data that support a causative impact of increased lymph node removal on 
improved pancreatic cancer survival outcomes are lacking. A minimum total LN count of 12 is 
recommended for pathologic staging of pancreatic cancer 7, although this requirement is not only 
not often met throughout the U.S. but missed in the majority of cases, based on population data 8-
11
. Meeting this expectation or exceeding it has been discussed as one possible aspect 
representing the quality of operative dissection and histopathologic analysis of pancreatectomy 
specimens, analogous to currently accepted guidelines for regional lymphatic dissection of 
colorectal cancers 11; nevertheless, controlling for operative versus pathologic influences on LN 
counts has been challenging for the concept of accepting LN counts as quality metric. This 
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analysis of a surgical experience with a consistent operative approach seeks to study institutional 
variability among LN counts and related parameters after pancreatectomy.  
 
 
Patients and Methods 
 
The analysis is based on prospectively collected data from a single surgeon’s consecutive 
pancreatectomy experience within four different institutions. These included a nonacademic 
tertiary cancer center (Institution A), a university HPB practice (B), an academic cancer center 
(C) and a community cancer center (D). All procedures were generally deemed to yield a 
complete resection with curative intent. Patients underwent some form of pancreatic resection 
including pancreatoduodenectomy (PD), distal pancreatectomy (DP), total pancreatectomy (TP) 
or others including central resection and enucleation. Resections performed for proven, suspected 
or possible malignant neoplasms all included standardized regional dissection components: 
pancreaticoduodenal, peripancreatic, common hepatic, retroportal, aortacaval and right lateral 
superior mesenteric LNs for PD; splenic and left gastric LNs for DP with splenic artery and vein 
resection but a preference for spleen preservation; and a combination of these for TP. Additional 
nodal areas were only included when deemed appropriate based on specific findings. Laproscopic 
DP became the preferred choice for cystic lesions and NETs since the early experience in 
institution B, and open DP remained the preferred choice for suspected PDAC or locally 
advanced tumors. Pathologic processing was done as per institutional standard protocols and was 
not influenced by the surgeon, but expectations to obtain LN counts beyond minimum staging 
requirements were communicated. Fat clearing methods were not routinely employed but 
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selectively utilized when deemed indicated by the pathologist based on fat content and the ability 
to grossly identify LNs. Standard nodal processing included bihalving and standard histologic 
H&E staining techniques; immunohistochemical techniques were not routinely applied. Requests 
for specimen reexamination were routinely directed towards the pathologist if total LN counts 
did not exceed 15. Demographic, clinicopathologic and outcomes data were collected 
prospectively based on institutional review board approved protocols. Postoperative morbidity 
was defined as minor for Clavien-Dindo grades of 1-2, and major for grades 3-5. Statistical 
analysis of covariates associated with various LN counts was performed using StatView software 
(SAS, Cary, NC). Significant relationships were examined with ANOVA, t-test, Mann-Whitney, 
Kruskal-Wallis, chi-square and logistic regression analyses, as indicated. Significance of 
differences was accepted at p<0.05. 
 
 
Results 
 
Of 315 patients who underwent pancretectomy, 54% were female and 46% male, with a median 
age of 65 years (range: 18-88). A proven cancer diagnosis was established in 239 (76%), 
including ductal or periampullary adenocarcinomas (n=204), neuroendocrine tumors (NETs, 
n=22), other malignancies (n=13); seventy-six patients had nonmalignant conditions including 
cystic neoplasms, benign NETs or focal pancreatitis. Operations included PD (69%), DP (26%), 
TP (1.3%) and others (4%); pylorus preservation was part of 91 PDs (42%). Preoperative therapy 
had been given in 10% of pancreatic ductal adenocarcinomas (PDAC). Patient distribution 
encompassed 33 in institution A (11%), 145 in B (46%), 86 in C (27%) and 51 in D (16%). The 
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breakdown of clinicopathologic and outcome parameters between institution cohorts is shown in 
Table 1. As listed, significant differences between institutions were identified for age, diagnoses 
and length of stay, but not regarding tumor size, R category and length of stay. Additional 
institutional differences existed in ASA class (p<0.0001), pathologic T category (p=0.04) and 
preoperative therapy (p=0.015). 
LNs were identified in 99% of PD, 100% of TP, 80% of DP, but 23% of other, lesser resection 
specimens (p<0.0001). Detailed metrics reflective of LN evaluation are listed in Table 1 and 
depicted in Figure 1. Total pathologic LN counts (median 16, range 1-88) differed between 
pancreatic/periampullary cancers (median: 19) and other diagnoses (median: 9; p<0.0001), and 
among procedures (PD: 17, DP: 14, total: 11, others: 2; p=0.048). Total LN counts in cancer 
patients did not have significant associations with preoperative therapy, ASA class or R category. 
Mean LN counts differed between institutions for both malignancies (A: 18, B: 13, C: 26, D: 26; 
p<0.0001) and benign diseases (A: 8.5, B: 5, C: 16 D: 18; p=0.003). Minimum total LN counts of 
10, 12 or 15 were reported in 80, 74 and 63% of cancer patients, respectively; frequencies ranged 
among institutions from 63-98% for 10+, 52-98% for 12+ and 34-92% for 15+ LNs examined 
(p<0.0001 for all three cut points; Table 1). There were no differences between institutions 
regarding number of positive LNs and percent of N+ staging categories for cancer patients. The 
number of positive LNs correlated to total LN counts (r=0.415, p<0.0001; Figure 1F). Nodal 
positivity for patients with pancreatic and periampullary malignancy was 49 vs. 66% below vs. at 
or above a cutpoint of 10 total LNs (p=0.034); for the 12 LN cutpoint, they were 52 and 67% 
(p=0.049), and for the 15 LN cutpoint 53 and 69%, respectively (p=0.022). When controlled for 
other covariates such as diagnosis and resection type, the institution was the only significant 
variable linked to the likelihood to obtain a total LN count of 15 or more; odds ratios compared 
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to institution A were 0.269 (95% CI: 0.1-0.7) for B (p=0.009), 3.01 for C (0.9-10.0, p=0.07) and 
6.8 for D (1.7-28.4, p=0.008). 
 
 
Discussion 
 
The potential clinical impact or value of lymphadenectomy for pancreatic and periampullary 
malignancies has been debated for some time. In contrast to other GI neoplasms such as gastric 
or colorectal cancer where standardized or extended LN dissection and formal examination of 12 
to 15 LNs may have a disease-control impact beyond the known staging benefit, most 
periampullary cancers are high-risk lesions with high propensity for distant metastasis and 
resulting poor survival odds, limiting the possibility of better regional disease control to result in 
superior survival outcomes. For this reason, convincing data to support higher LN counts to 
support greater overall survival or locoregional control rates do not exist. Nevertheless, 
population based analyses have shown an association of increased total or negative LN counts 
with better survival, independent of stage-specific survival 8,9. It is acknowledged, however, that 
higher LN counts may also be a surrogate for other variables such as greater administration of 
chemotherapy 11. Several randomized trials of extended LN dissection during pancreatectomy for 
cancer have failed to show convincing support for any survival benefit. Extending the regional 
dissection beyond a standard dissection has likely failed in this setting because the “standard” 
dissection already included reasonable LN groups for dissection and acceptable counts beyond 
which further lymphadenectomy is less likely to mediate further measurable benefit 3-5. 
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Should a minimum number of LNs examined thus be recommended for pancreas cancer 
resections? It is clear that throughout the US population, the minimum staging recommendation 
of 12 LNs is missed in the majority of cases 8-10. Under this perspective, creating a LN count 
based quality metric appears reasonable. However, the question of variability in pathologic 
examination may challenge the feasibility and reliability of such approach. Multi-institutional 
assessment of LN numbers would struggle with variability of surgical dissection practices, 
differences in patient cohorts and varying pathologic practices. The current series attempts to 
control for the operative variability by comparing pancreatectomy-associated LN counts in a 
single-surgeon experience within four different institutions. While methodologically not 
protected from possible biases as result of different patient populations, this approach 
nevertheless represents an intriguing opportunity for the ability to examine variations in LN 
counts based on institutional influences with consistent operative dissection standards. 
The results show that pancreatectomy-associated LN counts varied considerably between 
institutions. While the recommended staging requirements were met or exceeded in between 80 
to 98% of cases in three institutions, this was the case in just around half of cases in the fourth 
institution. Reasons will likely originate in gross pathologic specimen preparation and 
examination standards, but certainly could reflect other differences between institutions in patient 
overall health, nutrition status, therapeutic aspects etc. Reliable data that LN counts after 
pancreatectomy vary between institutions do not exist; however, examples from other disease 
types such as endometrial or colon cancers suggest that this is indeed the case 12,13. In addition, 
interobserver and intraobserver variability among pathologists is a well-documented 
phenomenon 14. Although is is methodologically challenging to define the impact of surgeon, 
pathologist, patient and institution on variations in the resulting LN count, it has been suggested 
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that for resected colon cancer, surgeon and pathologist impact was observed to be smaller than 
those of institution and patient variability 13. 
Should pathologists invest effort in finding additional LNs once a positive LN has been 
identified? While for pancreatic cancer this may be an appropriate question, for other 
nonpancreatic periampullary cancers with generally more moderate survival hazards this will be 
less debatable. For all these epithelial cancers, number of positive LNs as well as number of 
negative LNs (or total LN counts) have shown significant overall survival impact at least in large 
population database or multi-institutional trial analyses 6,8. Consequently, defining appropriate 
LN numbers seems to be a reasonable pathologic objective, if at a minimum to meet proper 
staging objectives. How relevant may LN counts be for benign conditions leading to resection? It 
should be noted that in the current series, in a considerable number of resections the definitive 
malignant or benign nature of the underlying process was not known at the time of the procedure, 
as for most neuroendocrine or mucinous cystic neoplasms, and that the resulting resection extent 
included regional dissection with splenic vascular resection in case a malignant process was to be 
identified. Interestingly, the institution with the lowest average LN counts for cancerous lesions 
also was found to have the lowest LN numbers reported for benign conditions. 
It appears noteworthy that the consistently highest counts in the current series were obtained in 
the community practice environment. Perhaps the proximity between surgeon and pathologist 
and the lack of potential challenges in a pathology laboratory training environment can lead to 
persistently diligent results. Along this notion, differences in LN counts for benign diagnoses 
may also result from a varying degree of importance lent to LN analysis in nonmalignant disease. 
The data also support an association between LN counts and nodal positivity, i.e. a greater 
sensitivity for staging and the potential for some stage migration with increasing LN counts up to 
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15. Based on these results, however, it would be difficult to delineate which exact cutoff point 
should be considered appropriate for pancreatic cancer resections. 
Limitations of this study relate to its modest size, the longitudinal comparison of four 
institutional cohorts over time, the (albeit unlikely) potential for changed operative practice, the 
retrospective nature of evaluation and confounding factors not discernable within the data set. 
Nonstandardized pathologic processing, variation in pathologic dissection technique such as 
routine fat clearing measures, variability between individual pathologists and lack of a separate 
pathologic review, often limitations to quality reporting of clinical series, are nevertheless 
precisely desirable shortcomings to be addressed in this study. It should be stated, however, that 
the results obtained herein are generally rather favorable compared to other institutions regarding 
LN counts, quality of staging, margin status assessment and other clinical aspects 6,11,15. 
Quality of staging and operative therapy for cancer is expected to become more heavily 
scrutinized in the near future, and metrics that may reflect value aspects could gain increasing 
clinical and financial importance. If LN counts are to be used as performance metric for 
pancreatic and periampullary cancers, goals should be clearly stated and gross as well as 
histopathologic examination procedures should be standardized. Surgeons are encouraged to take 
an active role not only in the operative and multidisciplinary aspects of cancer care but also 
within the diagnostic and pathologic staging domains. 
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Table 1 
 
Clinical and pathologic characteristics of patients undergoing pancreatectomy, by institution 
 
Characteristic Subgroup Total 
cohort Institution A Institution B Institution C Institution D p value 
Patients, n  315 33 145 86 51  
Gender, n Male 146 15 57 46 28 NS 
 Female 169 18 88 40 23  
Mean age, yrs 
(range)  
64.6 (18-
88) 62.7 (44-88) 65.2 (34-86) 61.3 (18-84) 69.5 (37-85) 0.001 
Diagnoses, n (%) PDAC 146 (46) 15 (45) 63 (43) 38 (44) 30 (59) 0.0004 
 periampullary 58 (19) 7 (22) 32 (22) 7 (8) 12 (23)  
 PNET 22 (8) 1 (3) 2 (1) 14 (16) 5 (10)  
 other cancer 13 (4) 1 (3) 8 (6) 4 (5) 0  
 no cancer 76 (23) 9 (27) 40 (28) 23 (27) 4 (8)  
Operative 
procedures, n (%) PD 218 (69) 27 (82) 99 (68) 58 (68) 34 (67) NS 
 DP 80 (25) 6 (18) 34 (24) 24 (28) 16 (31)  
 TP 4 (1) 0 2 (1) 2 (2) 0  
 others 13 (4) 0 10 (7) 2 (2) 1 (2)  
Mean tumor size, cm 
(SD)  3.5 (2.6) 3.3 (1.8) 3.4 (2.2) 4.1 (3.8) 3.3 (1.9) NS 
LNs identified in 
specimen, %  91.1 97 84.8 94.2 100 0.024 
Median overall LN 
count, n (range)  16 (0-88) 15.5 (0-39) 10 (0-39) 23 (0-88) 26 (2-51) <0.0001 
Median overall 
cancer patient LN 
count, n (range) 
 19 (1-88) 17 (4-39) 12 (1-39) 24 (5-88) 26 (8-41) <0.0001 
Median positive LN 
count, n (range)  1 (0-22) 1 (0-7) 1 (0-20) 2 (0-22) 1 (0-21) NS 
Median LN count 
without cancer 
diagnosis, n (range) 
 9 (0-65) 8 (0-30) 5 (0-25) 14 (0-65) 18 (1-51) 0.0009 
Cancer patients with 
10+ LNs, %  80.4 91.3 62.5 91.5 97.9 <0.0001 
Cancer patients with 
12+ LNs, %  74.2 82.6 52.1 88.1 97.9 <0.0001 
Cancer patients with 
15+ LNs, %  63.1 69.6 34.4 84.7 91.5 <0.0001 
Cancer patients with 
N+ disease, %  62.6 50.0 58.9 70.7 66.0 NS 
R category, n (%) R0 184 (82) 19 (83) 73 (75) 51 (86) 41 (87) NS 
 R1 38 (17) 3 (13) 24 (25) 7 (12) 5 (11)  
 R2 4 (1) 1 (4) 0 1 (2) 1 (2)  
Postoperative 
morbidity, % None 57.8 63.6 62.8 53.5 47.1 NS 
 Minor 26.3 24.3 23.4 27.9 33.3  
 Major 15.9 12.1 13.8 18.6 19.6  
Median length of 
stay, d (range)  9 12 9 8.5 8 0.0032 
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Figure Legends 
 
 
Figure 1  
 
Lymph node counts, by institution and other characteristics 
 
1A Mean total LN counts, by institution (n=315; error bars: 95% CI; p<0.0001) 
1B Mean total LN counts, pancreatic and periampullary cancers only, by institution (n=227; 
error bars: 95% CI; p<0.0001) 
1C Mean total LN counts, cancer diagnoses only, by procedure (pancreatoduodenectomy: 
n=181, total pancreatectomy: n=3, distal pancreatectomy: n=40, others: n=1; error bars: standard 
deviation; p=NS) 
1D Mean total LN counts, pancreatic and periampullary cancers only, by procedure 
(pancreatoduodenectomy: n=110, pylorus-preserving pancreatoduodenectomy: n=71; error bars: 
95% CI; p=0.0042) 
1E Mean positive LN counts, pancreatic and periampullary cancers only, by institution 
(n=227; error bars: 95% CI; p=NS) 
1F Correlation between total and positive LN counts, pancreatic and periampullary cancers 
only (n=227; scattergram with regression line and 95% CI; p<0.0001) 
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